Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Abstract Full Text (PDF, 260K) PPT slides of all figures Supplemental Material Index Alert me when this article is cited Citation Map Services Email this article Similar articles in this journal Similar articles in PubMed Alert me to new content in the JEM Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Langrish, C. L. Articles by Cua, D. J. Search for Related Content PubMed PubMed Citation Articles by Langrish, C. L. Articles by Cua, D. J. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Substance via MeSH Related Collections Related Article Social Bookmarking                            What's this?

¹ Discovery Research, DNAX Research Inc., Palo Alto, CA 94304
² Experimental Pathology and Pharmacology, DNAX Research Inc., Palo Alto, CA 94304
³ Bioinformatics, DNAX Research Inc., Palo Alto, CA 94304

CORRESPONDENCE Daniel J. Cua: daniel.cua{at}dnax.org

Top Abstract Results Discussion Materials and Methods References

 
Interleukin (IL)-23 is a heterodimeric cytokine composed of a unique p19 subunit, and a common p40 subunit shared with IL-12. IL-12 is important for the development of T helper (Th)1 cells that are essential for host defense and tumor suppression. In contrast, IL-23 does not promote the development of interferon-–producing Th1 cells, but is one of the essential factors required for the expansion of a pathogenic CD4⁺ T cell population, which is characterized by the production of IL-17, IL-17F, IL-6, and tumor necrosis factor. Gene expression analysis of IL-23–driven autoreactive T cells identified a unique expression pattern of proinflammatory cytokines and other novel factors, distinguishing them from IL-12–driven T cells. Using passive transfer studies, we confirm that these IL-23–dependent CD4⁺ T cells are highly pathogenic and essential for the establishment of organ-specific inflammation associated with central nervous system autoimmunity.

IL-23 plays a pivotal role in the establishment and maintenance of organ-specific inflammatory autoimmune diseases. In particular, we have demonstrated that IL-23–deficient (IL-23p19^–/–) mice are resistant to experimental autoimmune encephalomyelitis (EAE), collagen-induced arthritis (CIA; references 1, 2), and IBD (unpublished data), highlighting an important role of this cytokine in autoimmune pathogenesis. Although IL-23 shares a common p40 subunit with IL-12 (3), these cytokines have divergent activities. IL-12 is an important factor for the differentiation of naive T cells into IFN-–producing Th1 cells, is essential for antimicrobial responses (4, 5), and serves as a suppressor of human B cell tumors (6). IL-23–deficient mice display normal immune responses to acute microbial infections such as Toxoplasma gondii. (7). However, IFN-^–/– (8), IFN-R^–/– (9), IL-12Rß2^–/– (10), and IL-12p35^–/– mice (11, 12), which all lack critical components of the Th1–IFN- pathway, are highly susceptible to inflammatory autoimmune diseases, questioning whether IFN-–producing T cells have an essential role in autoimmune pathogenesis. In this paper, we demonstrate that IL-23 promotes a T cell population characterized by the production of IL-17, IL-17F, TNF, IL-6, and other additional novel factors. Upon adoptive transfer to naive recipient mice, this IL-23–dependent T cell subset invades the target organ and can promote the development of organ-specific autoimmune inflammation.

	Results

Top Abstract Results Discussion Materials and Methods References

 
Differential cytokine expression of central nervous system (CNS)–infiltrating CD4⁺ T cells
To study the role of IL-23 in autoimmune inflammatory disease pathogenesis, we used a CNS autoimmune model because the target organ is normally free of activated macrophages and CD4⁺ T cells (13); therefore, we can monitor the infiltration of inflammatory cells into the CNS during disease development. Just before disease onset, myelin-oligodendrocyte glycoprotein peptide (MOG)_35-55–primed WT mice exhibited a large influx of CNS-invading immune cells (Fig. 1 A). Surprisingly, although IL-23–deficient mice (IL-23p19^–/–) were completely EAE resistant, comparable numbers of immune cells invaded the CNS (Fig. 1 A). In vitro stimulation of the CNS-invading CD4⁺ cells showed equivalent number of MOG-specific, IFN-–producing cells in both the IL-23p19^–/– and WT mice (Fig. 1 B), suggesting that IL-23 is not required for T cell migration across the blood–brain barrier or for Th1 cell development. In addition, the presence of Th1 cells capable of producing IFN- within the CNS of IL-23–deficient mice is not sufficient to induce EAE. Intracellular cytokine analysis also detected IL-6, IL-17, and TNF in the CNS-infiltrating CD4⁺ T cells from WT mice. In contrast, CD4⁺ T cells isolated from IL-23p19^–/– mice displayed reduced IL-6 and undetectable IL-17 production (Fig. 1 B). TNF production was also markedly reduced in the IL-23p19^–/– cells, consistent with a previous paper suggesting that IL-23 is required for TNF production by CNS-infiltrating T cells (12). Ex vivo analysis of draining LN (DLN) cells from immunized WT and IL-23p19^–/– mice reflected the CNS data, with similar IFN- levels, but no IL-17 production by the IL-23p19^–/– cells (2, 14, 15). These results suggest that IL-23 is not required for Th1 development, but is essential for the development of autoantigen-specific, IL-17–producing CD4⁺ T cells.

View larger version (24K): [in this window] [in a new window]   Figure 1. T cells and inflammatory macrophages enter the CNS of MOG-immunized IL-23p19–/– mice. (A) Phenotypic analysis of CNS-infiltrating cells in the brains of WT and IL-23p19–/– mice at day 7 (before EAE onset) after immunization with MOG/CFA. (B) Intracellular cytokine staining of day 7 CNS-infiltrating cells from WT and IL-23p19–/– mice after 18 h of stimulation with 100 µg/ml MOG peptide, all plots are gated on live CD4+ T cells. Data are representative of five separate experiments.

 
IL-23 drives an IL-17–producing T cell population
To confirm our in vivo data, next we cultured antigen-primed DLN cells in vitro with IL-23 to analyze cytokine production and proinflammatory gene expression. DLN cells isolated from SJL mice immunized with proteolipid protein peptide (PLP)_139-151 were cultured in the presence of PLP, plus rIL-23, rIL-12, or medium alone. Immediately after ex vivo isolation, CD4⁺ PLP-specific IFN-–producing (Th1) cells and IL-17–producing (Th_IL-17) cells were identified in the isolated DLN cells after PMA restimulation (Fig. 2 A). Administration of rIL-23 promoted the expansion of Th_IL-17 cells, and reduced the growth of Th1 cells after 5 d of culture (Fig. 2, A and B). In contrast, addition of rIL-12 promoted Th1 but reduced Th_IL-17 growth (Fig. 2 A and B). These results are consistent with papers suggesting that IL-23 is required for the development and expansion of IL-17–producing CD4⁺ T cells (2, 16, 17). Both Th_IL-17 and Th1 cells also produced TNF (Fig. S1 A, available at http://www.jem.org/cgi/content/full/jem.20041257/DC1) and were characterized as CD4⁺ CD62L^lo CD44^hi, indicative of activated T cells; however, the Th_IL-17 cells displayed lower CD45RB expression (Fig. S1 B). Th_IL-17 CNS-infiltrating T cells isolated from myelin antigen-immunized mice are also CD62L^lo CD44^hi CD45RB^lo (unpublished data). DLN cells taken from IL-12p40^–/– mice, which lack both IL-12 and IL-23, could still be driven in culture with rIL-23 or rIL-12 to generate Th_IL-17 or Th1 cells, respectively (Fig. 2 C). This suggests that IL-12 and IL-23 are not required during in vivo priming for subsequent in vitro generation of IL-23 responsive Th_IL-17 cells.

View larger version (46K): [in this window] [in a new window]   Figure 2. IL-23 promotes the expansion of IL-17 producing CD4+ (ThIL-17) cells. (A) Intracellular IL-17 and IFN- production by CD4+ DLN cells isolated from PLP-immunized WT SJL mice, either immediately after ex vivo isolation, or cultured with PLP139-151 peptide plus either rIL-12, rIL-23, or no added cytokine for 5 d. All plots are gated on live CD4+ T cells. (B) Mean percentage (±1 SD of error) of CD4+ T cells producing IFN- or IL-17 in response to 5 d of culture with IL-12 or IL-23. *, Student's unpaired t test, P < 0.02, averaged from eight separate experiments. (C) Intracellular IL-17 and IFN- production by CD4+ DLN cells isolated from MOG-immunized p40–/– C57BL/6 either immediately after ex vivo isolation or cultured for 5 d with rIL-12 or rIL-23. All intracellular staining samples were restimulated with PMA/ionomycin for 4 h before analysis. All plots are gated on live CD4+ T cells and are representative of three independent experiments.

 
To address whether Th_IL-17 cells can be generated in vitro from naive T cells, without in vivo priming, we isolated TCR-transgenic naive CD4⁺ T cells from DO11.10 Tg x Rag^–/– mice, and stimulated them with anti-CD3/anti-CD28 in the presence of rIL-12 or rIL-23. By day 7, the cultured cells were all CD62L^lo, indicative of an activated phenotype (Fig. 3 A). Upon restimulation with PMA/ionomycin, a small number of these activated T cells produced IL-17 in the IL-23–driven culture. These results suggest that a subpopulation of naive T cells can respond to IL-23 upon in vitro activation. In contrast, IL-12–driven cells produced high levels of IFN- and no IL-17 in vitro (Fig. 3 B). The naive T cells are biased toward IFN- production after anti-CD3/anti-CD28 stimulation. In the absence of exogenous cytokines, a small number of T cells producing IFN- (5%) were present after anti-CD3/anti-CD28 stimulation (Fig. 3 B). The same frequency of IFN- producers were found in the IL-23 driven cultures, suggesting that during primary in vitro stimulation, IL-23 is unable to affect IFN- levels. As seen with SJL DLN cultured cells, three to four rounds of in vitro IL-23 stimulation lead to reduction of IFN- producers (unpublished data).

View larger version (26K): [in this window] [in a new window]   Figure 3. IL-23 drives a small population of naive T cells to produce IL-17 after in vitro activation. (A) Surface expression of CD62L on naive splenic DO11.10 x Rag–/– T cells, either analyzed immediately after isolation (ex vivo) or on day 7 after in vitro anti-CD3/anti-CD28 stimulation plus IL-12 or IL-23. (B) Intracellular cytokine staining of CD4+ DO11.10 x Rag–/– T cells on day 7 after in vitro anti-CD3/anti-CD28 stimulation plus IL-12 or IL-23. Cells were restimulated with PMA/ionomycin for 4 h before intracellular staining. (C) Naive DO11.10 x Rag–/– T cells were parked in BALB/c recipients and OVA/CFA immunized. DLN cells were restimulated, PMA/ionomycin and intracellular stained for IL-17 and IFN- or (D) surface stained for CD44 and CD62L. All plots are gated on CD4+ KJ1-26+ cells. Results are representative of two experiments.

 
Next, we parked purified naive DO11.10 Tg x Rag^–/– CD4⁺ T cells into BALB/c hosts. After OVA_323-339/CFA immunization, DLN cells were isolated 4 d later and analyzed immediately. A small subset of KJ1-26⁺ T cells were capable of producing IL-17 and were characterized as CD62L^lo and CD44^hi (Fig. 3, C and D). These results suggest that subcutaneous OVA_323-339/CFA priming, which induces IL-23 expression in the DLN (not depicted) and also induces IL-17–producing T cells (Fig. 3 C). Both Th1 and Th_IL-17 cells were present in the KJ1-26⁺ OVA-primed DLN, indicating that both Th1 and Th_IL-17 cells can be generated from naive T cells. However, it is likely that additional factors are required to enhance IL-23 responsiveness.

Gene expression pattern induced by IL-12 versus IL-23
Next, we compared the gene expression profile of rIL-23– or rIL-12–stimulated PLP-specific CD4⁺ T cells by real-time PCR to study the functional characteristics of these different cell populations. Both IL-12– and IL-23–driven cells expressed constitutive levels of IL-12Rß1 (unpublished data). IL-12 drives high expression of IL-12Rß2, but little IL-23R, consistent with the ability of these cells to respond to IL-12 (Fig. 4 A). IFN- and granzyme G expression was also significantly increased. Conversely, IL-23 drives high mRNA expression of IL-23R, but little IL-12Rß2, consistent with the ability of these cells to respond to IL-23 (Fig. 4 A). IL-17, IL-17F, IL-6, and TNF RNA levels were also significantly elevated; however, IFN- and granzyme G expression were dramatically reduced in the IL-23 driven cultures (Fig. 4 A). Integrin-3, which enhances cellular migration within the target organ during inflammation (18), was also up-regulated in the IL-23–driven cells. These results suggest that the IL-23–driven T cells may play an important role in organ-specific inflammation, but not immune surveillance, via the classical IL-12–dependent IFN- pathway. Further analysis of >200 lymphoid and myeloid-specific genes by real-time PCR, comparing total (lymphoid and myeloid) DLN cells cultured with rIL-23 or rIL-12 showed that 80% of the genes displayed comparable expression profiles (Fig. 4 B). Of the remaining genes showing divergence, IL-12 elevated expression of many host defense genes such as granzyme F, granzyme G, TRAIL, BLYS, IFN-, TRAIL R2, and FASL. However, IL-23 induced, in addition to IL-17 and IL-17F, elevated expression of genes such as CCL7, CCL17, CCL20, CCL22, CCR1, and GM-CSF. We are currently characterizing the molecular basis of the cellular responses to IL-12 versus IL-23 by microarray analysis. Preliminary data identifies that IL-12 specifically induced 306 genes (greater than fivefold), comprised of many cytotoxicity and host defense genes. In contrast, IL-23 specifically induced 162 genes (greater than fivefold), including numerous novel expression sequence tags with unknown functions in addition to a 34-fold increase of IL-17 (unpublished data). Together, these results suggest that IL-12, not IL-23, drives development of T cell–expressing host defense genes. The precise in vivo function of IL-23 is currently unclear. Its capacity to induce IL-17 and other proinflammatory factors appears important for neutrophil recruitment (17) and granuloma formation (19). However, when dysregulated, it causes inflammatory responses often associated with autoimmunity.

View larger version (27K): [in this window] [in a new window]   Figure 4. Gene expression analysis of IL-23 versus IL-12 driven T cells. (A) Quantitative analysis of mRNA expression levels of selected genes, comparing sorted CD4+ DLN cells isolated from PLP-immunized mice, either not cultured (ex vivo) or cultured with rIL-23 or rIL-12 for 10 d. (B) Quantitative analysis of mRNA expression levels of >200 selected genes, comparing total DLN cells isolated from PLP-immunized mice, cultured with either rIL-23 or rIL-12 for 10 d. All samples were activated with PMA/ionomycin for 4 h before RNA extraction and Taqman analysis. Results are normalized to a housekeeping gene, ubiquitin, and representative of two similar experiments.

 
Th_IL-17 cells are highly encephalogenic
To compare the capacity of Th1 versus Th_IL-17 cells to induce EAE pathology, we transferred IL-23– or IL-12–expanded PLP-specific cells to naive recipient mice. To confirm that both IL-23– and IL-12–cultured cells were viable in vivo and could cross the blood–brain barrier, cells were fluorescently labeled before passive transfer. 3 d after transfer, similar frequencies of labeled cells were detected in the blood, spleen, and CNS, regardless of whether they were cultured with IL-23 or IL-12, suggesting both Th1 and Th_IL-17 cells can survive in vivo and traffic to the CNS. In addition, the transferred cells also remained stable with respect to their IFN- or IL-17 production in vivo (Fig. 5 A). Labeled cells were still detectable 6 d after transfer, but with decreased mean fluorescence intensity in both groups, indicative of normal proliferation/division of the cells (unpublished data).

View larger version (44K): [in this window] [in a new window]   Figure 5. IL-17–producing ThIL-17 cells induce EAE. (A) PLP-primed DLN cells cultured with rIL-23 or rIL-12 for 10 d, labeled with CFSE (peak MFI = 4,654) and transferred (5 x 106 cells/mouse) into recipient WT SJL mice. Cells were tracked at day 3 after immunization, with further gating on splenic CFSE+ CD4+ cells to determine IFN- and IL-17 production by intracellular staining. (B) PLP-primed DLN cells cultured with either rIL-23 (squares) or rIL-12 (triangles) for 10 d, and transferred into WT SJL mice as either purified CD4+ cells (3 x 106 cells/mouse; n = 10/group; top), or as total DLN cells (7 x 106 cells/mouse; n = 3/group; bottom), with mean EAE scores recorded. (C) Mean EAE scores of WT recipient mice (n = 5/group) passively transferred with graded numbers of ThIL-17 cells: 1.2 x 106 ThIL-17 (closed squares), 3 x 105 ThIL-17 (closed triangles), 1.5 x 105 ThIL-17 (open circles), or 2.0 x 104 ThIL-17 (open diamonds). Results are summarized from two separate experiments. (D) Mean EAE scores of WT recipient mice (n = 5/group) passively transferred with either 5 x 105 ThIL-17 cells (open squares), 5 x 105 Th1 cells (open diamonds), or cotransferred with ThIL-17 plus Th1 cells (5 x 105 of each; closed triangles), or ThIL-17 plus sorted IFN-– cells (5 x 105 ThIL-17 plus 2 x 105 IFN-– cells; closed circles). (C–D) ThIL-17 cell numbers are calculated from intracellular cytokine staining analysis, with 3-5 x 106 total DLN cells passively transferred per recipient mouse.

 
Next, we determined the encephalogenicity of Th_IL-17 versus Th1 cell populations. Mice that received either IL-23–driven Th_IL-17 cells (either as purified CD4⁺ T cells or total DLN containing 3 x 10⁵ Th_IL-17 cells) showed severe clinical signs of EAE (Fig. 5 B). However, mice that received an equivalent number of IL-12–driven Th1 cells showed no clinical signs of EAE, suggesting that Th1 cells are less efficient at inducing EAE (Fig. 5 B). When graded numbers of Th_IL-17 were transferred into naive SJL mice, Th_IL-17 cell number directly correlated with disease severity, regardless of the number of Th1 cells present (Fig. 5 C). To determine whether the IFN-^– cells might negatively regulate EAE, next we cotransferred FACS-sorted IFN-^– cell population or Th1 cells with Th_IL-17 cells to recipient mice. Neither IFN-^– cells nor Th1 cells could reduce the Th_IL-17-mediated EAE pathology (Fig. 5 D), suggesting that the inability of Th1 cells to induce EAE was not due to regulatory components in the IL-12–driven cultures. In addition, we noted that short-term IL-12–driven cell populations (7 d) could contain a small number of contaminating IL-17–producing cells that can induce mild EAE (Fig. 5 D). These results demonstrate that IL-17–producing T cells are more pathogenic than IFN-–producing T cells.

To test whether IL-17 production directly contributes to EAE severity, PLP-immunized WT SJL mice were treated with neutralizing antibodies against IL-17 (Fig. 6 A). Anti–IL-17 treatment resulted in partial protection from EAE, consistent with a recent paper suggesting that IL-17–deficient mice are resistant to actively induced EAE and CIA (20), and confirming that the IL-23–IL-17 pathway is important in inflammatory autoimmune diseases. However, the observed partial protection indicates that other factors induced by IL-23, including IL-6, IL-17F, and TNF, are also important in EAE pathogenesis. Indeed, the highly intense disease induced by passive transfer of Th_IL-17 cells (3–5 x 10⁵ cells/recipient) cannot be blocked by anti–IL-17 antibody treatment of recipient mice (unpublished data), suggesting that multiple factors produced by these exceptionally pathogenic Th_IL-17 cells must be neutralized before inhibiting their actions. In addition, IL-17 may also have a role in the initial expansion of the Th_IL-17 cells as suggested by a recent paper showing a role for IL-17 during immune priming (21). It was previously unclear whether the classical Th1-type/IFN-–mediated immune response is essential for induction or maintenance of autoimmune disease. Treatments with IFN- lead to disease exacerbation in human MS (22), and transgenic mice overexpressing IFN- in the CNS showed increased oligodendrocyte death leading to demyelinating diseases (23, 24). However, despite the potential toxic effects of IFN- in the CNS, mice that lack critical components of the Th1–IFN- pathway are highly susceptible to EAE (8–12). Consistent with this, treatment of PLP-immunized mice with neutralizing antibodies against IFN- demonstrated intensified disease leading to >75% mortality (Fig. 6 B), indicating that loss of IFN- results in disease exacerbation.

View larger version (17K): [in this window] [in a new window]   Figure 6. IL-17, not IFN-, contributes to EAE severity. (A) WT SJL mice actively immunized with PLP emulsified in CFA, and treated at day 7 with 200 µg anti–IL-17 (closed diamonds) or isotype control (open diamonds), n = 5/group. (B) WT SJL mice actively immunized with PLP emulsified in CFA (using suboptimal immunization strategy to give weaker disease), and treated at days 0 and 7 with 200 µg anti–IFN- (closed squares) or isotype control (open squares), n = 7/group. Plots are representative of three similar experiments.

 

	Discussion

Top Abstract Results Discussion Materials and Methods References

 
In this paper, we have identified a pathogenic T cell population critical for autoimmune inflammation. This IL-23–mediated immune response is not associated with IFN- or IL-4 production. IL-23 promotes the development and expansion of activated CD4⁺ cells that produce IL-17, IL-17F, IL-6, and TNF upon antigen-specific stimulation. Genetic analysis of these Th_IL-17 cells identified a unique expression pattern of proinflammatory cytokines and other novel factors. This data, plus the observation that IFN-–producing cells, are present in EAE-resistant, IL-23–deficient mice, suggesting that the IL-23–driven immune response is independent of the IFN-–Th1 pathway. IL-17 production was undetectable in CD4⁺ T cells from IL-23–deficient mice (derived from either CNS or LN), suggesting that IL-23 is essential for the development of autoantigen-specific T cell production of IL-17. By in vitro expansion of antigen-primed DLN cells with rIL-23 and passive transfer studies, we confirm that these IL-23–dependent T cells are highly pathogenic, and essential for the establishment of organ-specific inflammation associated with autoimmunity.

In key published EAE passive transfer papers (25, 26), PLP-primed DLN cells were cultured with rIL-12 for 4 d before transfer of 20–30 x 10⁶ cells into recipient mice. Both Th1 and Th_IL-17 cells can be found in antigen-primed DLN cells immediately after isolation; however, they reduce over time when cultured with IL-23 or IL-12, respectively. 4 d in the presence of rIL-12 is not sufficient time for the complete loss of IL-17 production; therefore, the cells were cultured for 10–14 d with either IL-12 or IL-23 before passive transfer. Our data indicates that the Th_IL-17 cells are far more efficient than Th1 cells at inducing EAE; as a result, we transferred 10-fold fewer cells in comparison to the published reports.

A recent paper demonstrated that antigen-primed IFN-⁺ versus IFN-^– cells have differential in vivo survival potentials (27). The IFN-⁺ cells were short-lived and performed immediate effector functions, whereas the IFN-^– cells had increased durability and possessed long-term memory function. This is consistent with our work demonstrating the existence of an IFN-^– IL-17⁺–producing T cell population. In addition, some but not all IFN-^– cells could produce IFN- at a later stage after strong antigenic stimulation in the presence of IL-12 (27), suggesting a shared a precursor lineage. In our studies, antigen-primed activated T cells are responsive to both IL-12 and IL-23. In short-term in vitro assays, CD62L^hi naive T cells appear to predominately respond to IL-12 and are biased toward IFN- production after anti-CD3 and anti-CD28 stimulation (Fig. 3, A and B, and reference 3). In vitro activation of naive T cells in the presence of IL-23 could induce the generation of a small population of IL-17–producing T cells; however, during this short-term culture, IL-23 was unable to affect residual IFN- production. It is likely that during in vivo activation of naive T cells, an array of cytokines and cellular interactions are required to optimally induce IL-23 responsiveness. For example, naive T cells from autoimmune-prone DBA-1 mice can be driven to produce IL-17 when alternatively stimulated via ICOS (28).

The in vivo function of IL-23 remains to be determined, but appears to be clearly associated with IL-17, IL-17F, IL-6, and TNF production. IL-17 is an important effector cytokine during inflammation. IL-17–deficient mice are resistant to CIA and EAE (20), and therapeutic treatment with an IL-17 antagonist antibody can reverse ongoing CIA (29), consistent with the notion that IL-17 functions during the effector phase of an inflammatory response. In addition, IL-17 has been found in many human autoimmune diseases, including multiple sclerosis (30), rheumatoid arthritis (31), and psoriasis (32). IL-17–producing T cells have also been identified in the synovial fluid of patients with Lyme arthritis (33), suggesting involvement of IL-17 in infection-induced immunopathology. IL-17 receptors that bind both IL-17 and IL-17F are ubiquitously expressed in a broad range of cell types including myeloid and endothelial cells. Engagement of IL-17 and/or IL-17F on these cell types promotes expression of IL-1, IL-6, IL-8, TNF, and ICAM-1, which are all critical factors that drive inflammation (34).

IL-6 is predominately produced by myeloid cells and is an important factor promoting inflammatory responses. The production of IL-6 by Th_IL-17 but not Th1 cells is intriguing and may explain the hyperencephalogenicity of Th_IL-17 cells. IL-6 produced by LPS-activated dendritic cells can turn off regulatory T cell (T reg cell) function, allowing effector T cell activation (35). It is tempting to speculate that in the absence of microbe-activated dendritic cells, the IL-6–producing Th_IL-17 cells may have the potential to directly inhibit the action of T reg cell function within the target organ during autoimmune inflammation. The role of TNF in chronic inflammatory diseases is well recognized (36). Interestingly, TNF is produced by both Th1 and Th_IL-17 cells after in vitro stimulation, suggesting that TNF may play a role in both IL-12 and IL-23 linked immune responses. Thus, the cellular mechanism of action of IL-23 in autoimmunity is the expansion of self-reactive IL-17, IL-17F, TNF, and IL-6–producing T cells. Importantly, this IL-23–mediated immune response has a different gene expression pattern than IL-12–driven T cell responses. Understanding the molecular basis for the differential gene expression pattern of the IL-23–dependent T cell population could provide additional therapeutic targets for the treatment of inflammatory autoimmune diseases.

	Materials and Methods

Top Abstract Results Discussion Materials and Methods References

 
Mice
IL-23p19^–/– (IL-23–deficient mice) and their WT controls were generated on a mixed B6 x 129 background using approaches described previously (1).

SJL/J and IL-12p40–deficient (p40^–/– C57BL/6) mice were obtained from The Jackson Laboratory. All animal procedures were approved by the DNAX IACUC committee, in accordance with AAALAC guidelines.

EAE
EAE was induced in female mice at 8–12 wk and clinically assessed as described previously (1), using 100 µg MOG_35-55 per mouse for B6 x 129 and C57BL/6 strains, or 80 µg PLP_139-151 (PLP) per mouse for SJL strains and emulsified in CFA. Where required, brain- and spinal cord–infiltrating cells were isolated from MOG-immunized WT and IL-23p19^–/– mice at day 7 (before EAE onset; reference 1), and cultured with 100 µg/ml MOG for 18 h (plus Golgi-Plug for final 4 h) before intracellular cytokine staining.

Intracellular cytokine flow cytometry.
Cells were surface stained with anti–CD4-FITC in the presence of Fc blocking antibodies. Cells were washed, fixed, permeabilized with Cytofix/Cytoperm buffer and intracellular stained with antibodies against IFN-/TNF/IL-17/IL-6/IL-4, and analyzed with a FACScalibur flow cytometer. For DLN and naive T cell intracellular cytokine staining, samples were restimulated with 50 ng/ml PMA and 500 ng/ml ionomycin (Sigma-Aldrich) in the presence of Golgi-plug for 4 h, before surface staining with combinations of antibodies against CD4/CD45RB/CD62L/CD44 and intracellular cytokine staining with combinations of antibodies against IFN-/IL-17/TNF/IL-4. All antibodies and staining buffers were purchased from BD Biosciences.

DLN cultures and passive transfer
Inguinal, axillary, and branchial LNs were harvested from SJL mice 9 d after antigen immunization. DLN cells were cultured in complete RPMI 1640 media containing 10% FCS, supplemented with Pen-Strep, L-glutamine, Hepes, sodium pyruvate, and 2-ME, in the presence of 20 µg/ml PLP_139-151 for an initial 5 d, plus addition of either 10 ng/ml rIL-12 or 10 ng/ml rIL-23. Media was replaced on days 5 and 8 and supplemented with 2 ng/ml IL-2 (BD Biosciences), plus rIL-23 or rIL-12. At day 5, cells initially cultured with IL-12 were rested without IL-12 for 3 d to prevent excessive apoptosis. As required, day 10 cultured DLN cells were positively selected and enriched using CD4⁺ microbeads (Miltenyi Biotec) with >95% purity. For passive transfer, SJL DLN cells (either total DLN or CD4⁺ MACS enriched) were harvested, washed in RPMI 1640, and injected i.v. into naive WT female SJL mice (see Fig. 5 for culture conditions and cell number in each experiment). The frequency of Th_IL-17 and Th1 cells was calculated by intracellular flow cytometry performed in parallel for each sample. For IL-12p40^–/– cultures, DLN cells were harvested from p40^–/– mice at day 9 after MOG immunization and cultured with 100 µg/ml MOG_35-55 peptide plus 10 ng/ml rIL-12 or 10 ng/ml rIL-23 for 5 d before analysis.

Naive T cell cultures and adoptive transfer.
DLN and spleen cells were isolated from naive DO11.10 Tg x Rag^–/– mice, and CD4⁺ cells were purified by MACS. For culture, 10⁶ naive CD4⁺ spleen cells/ml were activated for 3 d with 10 µg/ml of plate-bound anti-CD3 and 1 µg/ml anti-CD28 with 10 ng/ml rIL-12 or 10 ng/ml rIL-23. Cultured cells were rested for 4 d before restimulation with PMA/ionomycin in the presence of Golgi-plug for intracellular cytokine staining on day 7. For adoptive transfer, pooled naive CD4⁺ MACS-purified spleen and LN cells from DO11.10 Tg x Rag^–/– mice were pooled and injected into recipient BALB/c mice, with each mouse receiving 5 x 10⁶ CD4⁺ KJ1-26⁺ cells. Recipient mice were immunized with 20 µg OVA_323-339 peptide emulsified in CFA on day 2, and the DLN cells were harvested on day 6 and immediately analyzed for intracellular cytokine staining after PMA/ionomycin restimulation. Where required, cells were surface stained with combinations of fluorescently labeled antibodies KJ1-26, CD4, CD62L, and CD44.

Gene expression analysis.
RNA was extracted from DLN cells isolated from naive SJL non–PLP-primed control mice (unprimed), and as total DLN or CD4⁺ MACS-enriched cells from PLP-immunized mice. These cells were either not cultured (ex vivo) or cultured with rIL-23 or rIL-12 for 10 d. All samples were activated with 50 ng/ml PMA and 500 ng/ml ionomycin (Sigma-Aldrich) for 4 h before cDNA preparation. mRNA expression was quantitated by real-time PCR as described previously (2).

Fluorescent dye staining and tracking.
SJL DLN cells cultured for 10 d with either IL-23 or IL-12 were labeled with CFSE (Molecular Probes), transferred i.v. into naive recipient mice (5 x 10⁶ total cells/mouse). At day 3 after transfer, spleens were removed and homogenized, red blood cells were lysed, and mononuclear cells were surface stained with anti–CD4-APC and intracellular stained with anti–IL-17 or anti–IFN- as described before. Blood was collected and lysed (RBC lysis buffer; Sigma-Aldrich), and mononuclear cells from brains and spinal cord tissue were prepared as described previously (1) and surface stained with anti–CD4-APC.

Sorting of IFN-⁺ and IFN- DLN cells
IFN-⁺ and IFN-^– cells were sorted from PLP-primed SJL DLN cells cultured with rIL-12 for 10 d, after 3 h stimulation with anti-CD3/anti-CD28, using anti-CD45 anti–IFN- bispecific antibody-capture matrix kit (Miltenyi Biotec) as described previously (27).

Antibody treatment of EAE.
WT SJL mice were treated with 200 µg i.p anti–IL-17 (clone 18H10, rat IgG1), or treated with anti–IFN- (clone XMG1.2, rat IgG1) or relevant isotype controls, immunized with PLP_139-151 as described before. Both neutralizing antibodies were generated at DNAX (with <4 EU/mg of mAb); however, they are also commercially available from BD Biosciences, Southern Biotechnology Associates, Inc., and Upstate Biotechnology.

Online supplemental material
Fig. S1 demonstrates that both Th_IL-17 and Th1 cells produce TNF, but not IL-4, and are phenotypically characterized as CD4⁺CD44^hiCD62L^lo indicative of activated T cells. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20041257/DC1.

	Acknowledgments

This work was fully supported by Schering-Plough Corporation. The authors have no other conflicting financial interests.

Submitted: 24 June 2004
Accepted: 6 December 2004

	References

Top Abstract Results Discussion Materials and Methods References

 

1 Cua, D.J., J. Sherlock, Y. Chen, C.A. Murphy, B. Joyce, B. Seymour, L. Lucian, W. To, S. Kwan, T. Churakova, et al. 2003. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 421:744–748.[CrossRef][Medline]

2 Murphy, C.A., C.L. Langrish, Y. Chen, W. Blumenschein, T. McClanahan, R.A. Kastelein, J.D. Sedgwick, and D.J. Cua. 2003. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 198:1951–1957.[Abstract/Free Full Text]

3 Oppmann, B., R. Lesley, B. Blom, J.C. Timans, Y. Xu, B. Hunte, F. Vega, N. Yu, J. Wang, K. Singh, et al. 2000. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 13:715–725.[CrossRef][Medline]

4 O'Garra, A., and N. Arai. 2000. The molecular basis of T helper 1 and T helper 2 cell differentiation. Trends Cell Biol. 10:542–550.[CrossRef][Medline]

5 Shtrichman, R., and C.E. Sanuel. 2001. The role of gamma interferon in antimicrobial immunity. Curr. Opin. Microbiol. 4:251–259.[CrossRef][Medline]

6 Airoldi, I., E. Di Carlo, B. Banelli, L. Moserle, C. Cocco, A. Pezzolo, C. Sorrentino, E. Rossi, M. Romani, A. Amadori, and V. Pistoia. 2004. The IL-12Rbeta2 gene functions as a tumor suppressor in human B cell malignancies. J. Clin. Invest. 113:1651–1659.[CrossRef][Medline]

7 Lieberman, L.A., F. Cardillo, A.M. Owyang, D.M. Rennick, D.J. Cua, R.A. Kastelein, and C.A. Hunter. 2004. IL-23 provides a limited mechanism of resistance to acute toxoplasmosis in the absence of IL-12. J. Immunol. 173:1887–1893.[Abstract/Free Full Text]

8 Ferber, I., S. Brocke, C. Taylor-Edwards, W. Ridgway, C. Dinisco, L. Steinman, D. Dalton, and C. Fathman. 1996. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J. Immunol. 156:5–7.[Abstract]

9 Willenborg, D.O., S. Fordham, C.C. Bernard, W.B. Cowden, and I.A. Ramshaw. 1996. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J. Immunol. 157:3223–3227.[Abstract]

10 Zhang, G., B. Gran, S. Yu, J. Li, I. Siglienti, X. Chen, M. Kamoun, and A. Rostami. 2003. Induction of experimental autoimmune encephalomyelitis in IL-12 receptor-beta 2-deficient mice: IL-12 responsiveness is not required in the pathogenesis of inflammatory demyelination in the central nervous system. J. Immunol. 170:2153–2160.[Abstract/Free Full Text]

11 Becher, B., B.G. Durell, and R.J. Noelle. 2002. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J. Clin. Invest. 110:493–497.[CrossRef][Medline]

12 Gran, B., G. Zhang, S. Yu, J. Li, X. Chen, E. Ventura, M. Kamoun, and A. Rostami. 2002. IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J. Immunol. 169:7104–7110.[Abstract/Free Full Text]

13 Hickey, W.F. 1991. Migration of hematogenous cells through the blood-brain barrier and the initiation of CNS inflammation. Brain Pathol. 1:97–105.[Medline]

14 Ghilardi, N., N. Kljavin, Q. Chen, S. Lucas, A.L. Gurney, and F.J. De Sauvage. J. 2004. Compromised humoral and delayed-type hypersensitivity responses in IL-23-deficient mice. J. Immunol. 172:2827–2833.[Abstract/Free Full Text]

15 Aggarwal, S., N. Ghilardi, M.H. Xie, F.J. de Sauvage, and A.L. Gurney. 2003. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278:1910–1914.[Abstract/Free Full Text]

16 Aarvak, T., M. Chabaud, P. Miossec, and J.B. Natvig. 1999. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J. Immunol. 162:1246–1251.[Abstract/Free Full Text]

17 Happel, K.I., M. Zheng, E. Young, L.J. Quinton, E. Lockhart, A.J. Ramsay, J.E. Shellito, J.R. Schurr, G.J. Bagby, S. Nelson, and J.K. Kolls. 2003. Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection. J. Immunol. 170:4432–4436.[Abstract/Free Full Text]

18 Takada, Y., E.A. Wayner, W.G. Carter, and M.E. Hemler. 1988. Extracellular matrix receptors, ECMRII and ECMRI, for collagen and fibronectin correspond to VLA-2 and VLA-3 in the VLA family of heterodimers. J. Cell. Biochem. 37:385–393.[CrossRef][Medline]

19 Holscher, C., R.A. Atkinson, B. Arendse, N. Brown, E. Myburgh, G. Alber, and F. Brombacher. 2001. A protective and agonistic function of IL-12p40 in mycobacterial infection. J. Immunol. 167:6957–6966.[Abstract/Free Full Text]

20 Nakae, S., A. Nambu, K. Sudo, and Y. Iwakura. 2003. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. 171:6173–6177.[Abstract/Free Full Text]

21 Nakae, S., S. Saijo, R. Horai, K. Sudo, S. Mori, and Y. Iwakura. 2003. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc. Natl. Acad. Sci. USA. 100:5986–5990.[Abstract/Free Full Text]

22 Panitch, H.S., R.L. Hirsch, A.S. Haley, and K.P. Johnson. 1987. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet. 1:893–895.[Medline]

23 Renno, T., V. Taupin, L. Bourbonniere, G. Verge, E. Tran, R. De Simone, M. Krakowski, M. Rodriguez, A. Peterson, and T. Owens. 1998. Interferon-gamma in progression to chronic demyelination and neurological deficit following acute EAE. Mol. Cell. Neurosci. 12:376–389.[CrossRef][Medline]

24 Vartanian, T., Y. Li, M. Zhao, and K. Stefansson. 1995. Interferon-gamma-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. Mol. Med. 1:732–743.[Medline]

25 Leonard, J.P., K.E. Waldburger, and S.J. Goldman. 1995. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J. Exp. Med. 181:381–386.[Abstract/Free Full Text]

26 Segal, B.M., and E.M. Shevach. 1996. IL-12 unmasks latent autoimmune disease in resistant mice. J. Exp. Med. 184:771–775.[Abstract/Free Full Text]

27 Wu, C.Y., J.R. Kirman, M.J. Rotte, D.F. Davey, S.P. Perfetto, E.G. Rhee, B.L. Freidag, B.J. Hill, D.C. Douek, and R.A. Seder. 2002. Distinct lineages of T(H)1 cells have differential capacities for memory cell generation in vivo. Nat. Immunol. 3:852–858.[CrossRef][Medline]

28 Nurieva, R.I., P. Treuting, J. Duong, R.A. Flavell, and C. Dong. 2003. Inducible costimulator is essential for collagen-induced arthritis. J. Clin. Invest. 111:701–706.[Medline]

29 Lubberts, E., M.I. Koenders, B. Oppers-Walgreen, L. van den Bersselaar, C.J. Coenen-de Roo, L.A. Joosten, and W.B. van den Berg. 2004. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 50:650–659.[CrossRef][Medline]

30 Matusevicius, D., P. Kivisakk, B. He, N. Kostulas, V. Ozenci, S. Fredrikson, and H. Link. 1999. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult. Scler. 5:101–104.[Abstract/Free Full Text]

31 Ziolkowska, M., A. Koc, G. Luszezykiewicz, K. Ksiezopolska-Pietrzak, E. Klimczak, H. Chwalinska-Sadowska, and W. Maslinski. 2000. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J. Immunol. 164:2832–2838.[Abstract/Free Full Text]

32 Teunissen, M.B., C.W. Koomen, R. De Waal Malefyt, E.A. Wierenga, and J.D. Bos. 1998. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J. Invest. Dermatol. 111:645–649.[CrossRef][Medline]

33 Infante-Duarte, C., H.F. Horton, M.C. Byrne, and T. Kamradt. 2000. Microbial lipopeptides induce the production of IL-17 in Th cells. J. Immunol. 165:6107–6115.[Abstract/Free Full Text]

34 Aggarwal, S., and A. Gurney. 2002. IL-17: prototype member of an emerging cytokine family. J. Leukoc. Biol. 71:1–8.[Abstract/Free Full Text]

35 Pasare, C., and R. Medzhitov. 2003. Toll pathway–dependent blockade of CD4+CD25+ T cell–mediated suppression by dendritic cells. Science. 299:1033–1036.[Abstract/Free Full Text]

36 Feldmann, M. 2002. Development of anti-TNF therapy for rheumatoid arthritis. Nat. Rev. Immunol. 2:364–371.[CrossRef][Medline]

CiteULike

Complore

Connotea

Del.icio.us

Digg

Facebook

Reddit

Technorati

Twitter

This article has been cited by other articles:

• Tanaka, S., Yoshimoto, T., Naka, T., Nakae, S., Iwakura, Y.-i., Cua, D., Kubo, M. (2009). Natural Occurring IL-17 Producing T Cells Regulate the Initial Phase of Neutrophil Mediated Airway Responses. J. Immunol. 183: 7523-7530 [Abstract] [Full Text]  
• Shi, G., Ramaswamy, M., Vistica, B. P., Cox, C. A., Tan, C., Wawrousek, E. F., Siegel, R. M., Gery, I. (2009). Unlike Th1, Th17 Cells Mediate Sustained Autoimmune Inflammation and Are Highly Resistant to Restimulation-Induced Cell Death. J. Immunol. 183: 7547-7556 [Abstract] [Full Text]  
• Jager, A., Dardalhon, V., Sobel, R. A., Bettelli, E., Kuchroo, V. K. (2009). Th1, Th17, and Th9 Effector Cells Induce Experimental Autoimmune Encephalomyelitis with Different Pathological Phenotypes. J. Immunol. 183: 7169-7177 [Abstract] [Full Text]  
• Wenink, M. H., Santegoets, K. C. M., Broen, J. C. A., van Bon, L., Abdollahi-Roodsaz, S., Popa, C., Huijbens, R., Remijn, T., Lubberts, E., van Riel, P. L. C. M., van den Berg, W. B., Radstake, T. R. D. J. (2009). TLR2 Promotes Th2/Th17 Responses via TLR4 and TLR7/8 by Abrogating the Type I IFN Amplification Loop. J. Immunol. 183: 6960-6970 [Abstract] [Full Text]  
• Canonigo-Balancio, A. J., Fos, C., Prod'homme, T., Becart, S., Altman, A. (2009). SLAT/Def6 Plays a Critical Role in the Development of Th17 Cell-Mediated Experimental Autoimmune Encephalomyelitis. J. Immunol. 183: 7259-7267 [Abstract] [Full Text]  
• Oyamada, A., Ikebe, H., Itsumi, M., Saiwai, H., Okada, S., Shimoda, K., Iwakura, Y., Nakayama, K. I., Iwamoto, Y., Yoshikai, Y., Yamada, H. (2009). Tyrosine Kinase 2 Plays Critical Roles in the Pathogenic CD4 T Cell Responses for the Development of Experimental Autoimmune Encephalomyelitis. J. Immunol. 183: 7539-7546 [Abstract] [Full Text]  
• Kwan, B. C.-H., Tam, L.-S., Lai, K.-B., Lai, F. M.-M., Li, E. K.-M., Wang, G., Chow, K.-M., Li, P. K.-T., Szeto, C.-C. (2009). The gene expression of type 17 T-helper cell-related cytokines in the urinary sediment of patients with systemic lupus erythematosus. Rheumatology (Oxford) 48: 1491-1497 [Abstract] [Full Text]  
• Hillyer, P., Larche, M. J., Bowman, E. P., McClanahan, T. K., de Waal Malefyt, R., Schewitz, L. P., Giddins, G., Feldmann, M., Kastelein, R. A., Brennan, F. M. (2009). Investigating the role of the interleukin-23/-17A axis in rheumatoid arthritis. Rheumatology (Oxford) 48: 1581-1589 [Abstract] [Full Text]  
• Brucklacher-Waldert, V., Stuerner, K., Kolster, M., Wolthausen, J., Tolosa, E. (2009). Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 0: awp289v1-awp289 [Abstract] [Full Text]  
• Nizri, E., Irony-Tur-Sinai, M., Lory, O., Orr-Urtreger, A., Lavi, E., Brenner, T. (2009). Activation of the Cholinergic Anti-Inflammatory System by Nicotine Attenuates Neuroinflammation via Suppression of Th1 and Th17 Responses. J. Immunol. 183: 6681-6688 [Abstract] [Full Text]  
• Zhang, Y., Reynolds, J. M., Chang, S. H., Martin-Orozco, N., Chung, Y., Nurieva, R. I., Dong, C. (2009). MKP-1 Is Necessary for T Cell Activation and Function. J. Biol. Chem. 284: 30815-30824 [Abstract] [Full Text]  
• Zhou, X., Chen, Q., Moore, J., Kolls, J. K., Halperin, S., Wang, J. (2009). Critical Role of the Interleukin-17/Interleukin-17 Receptor Axis in Regulating Host Susceptibility to Respiratory Infection with Chlamydia Species. Infect. Immun. 77: 5059-5070 [Abstract] [Full Text]  
• Jeffery, L. E., Burke, F., Mura, M., Zheng, Y., Qureshi, O. S., Hewison, M., Walker, L. S. K., Lammas, D. A., Raza, K., Sansom, D. M. (2009). 1,25-Dihydroxyvitamin D3 and IL-2 Combine to Inhibit T Cell Production of Inflammatory Cytokines and Promote Development of Regulatory T Cells Expressing CTLA-4 and FoxP3. J. Immunol. 183: 5458-5467 [Abstract] [Full Text]  
• Smith, E., von Vietinghoff, S., Stark, M. A., Zarbock, A., Sanders, J. M., Duley, A., Rivera-Nieves, J., Bender, T. P., Ley, K. (2009). T-Lineage Cells Require the Thymus but Not V(D)J Recombination to Produce IL-17A and Regulate Granulopoiesis In Vivo. J. Immunol. 183: 5685-5693 [Abstract] [Full Text]  
• Tigno-Aranjuez, J. T., Jaini, R., Tuohy, V. K., Lehmann, P. V., Tary-Lehmann, M. (2009). Encephalitogenicity of Complete Freund's Adjuvant Relative to CpG Is Linked to Induction of Th17 Cells. J. Immunol. 183: 5654-5661 [Abstract] [Full Text]  
• Das, J., Ren, G., Zhang, L., Roberts, A. I., Zhao, X., Bothwell, A. L.M., Van Kaer, L., Shi, Y., Das, G. (2009). Transforming growth factor {beta} is dispensable for the molecular orchestration of Th17 cell differentiation. JEM 206: 2407-2416 [Abstract] [Full Text]  
• Crowe, C. R., Chen, K., Pociask, D. A., Alcorn, J. F., Krivich, C., Enelow, R. I., Ross, T. M., Witztum, J. L., Kolls, J. K. (2009). Critical Role of IL-17RA in Immunopathology of Influenza Infection. J. Immunol. 183: 5301-5310 [Abstract] [Full Text]  
• El-behi, M., Ciric, B., Yu, S., Zhang, G.-X., Fitzgerald, D. C., Rostami, A. (2009). Differential Effect of IL-27 on Developing versus Committed Th17 Cells. J. Immunol. 183: 4957-4967 [Abstract] [Full Text]  
• Kim, Y.-S., Hong, S.-W., Choi, J.-P., Shin, T.-S., Moon, H.-G., Choi, E.-J., Jeon, S. G., Oh, S.-Y., Gho, Y. S., Zhu, Z., Kim, Y.-K. (2009). Vascular Endothelial Growth Factor Is a Key Mediator in the Development of T Cell Priming and Its Polarization to Type 1 and Type 17 T Helper Cells in the Airways. J. Immunol. 183: 5113-5120 [Abstract] [Full Text]  
• Wan, Y. Y., Flavell, R. A. (2009). How Diverse--CD4 Effector T Cells and their Functions. J Mol Cell Biol 1: 20-36 [Abstract] [Full Text]  
• Steinmetz, O. M., Turner, J.-E., Paust, H.-J., Lindner, M., Peters, A., Heiss, K., Velden, J., Hopfer, H., Fehr, S., Krieger, T., Meyer-Schwesinger, C., Meyer, T. N., Helmchen, U., Mittrucker, H.-W., Stahl, R. A. K., Panzer, U. (2009). CXCR3 Mediates Renal Th1 and Th17 Immune Response in Murine Lupus Nephritis. J. Immunol. 183: 4693-4704 [Abstract] [Full Text]  
• Mizuguchi, M., Asao, H., Hara, T., Higuchi, M., Fujii, M., Nakamura, M. (2009). Transcriptional Activation of the Interleukin-21 Gene and Its Receptor Gene by Human T-cell Leukemia Virus Type 1 Tax in Human T-cells. J. Biol. Chem. 284: 25501-25511 [Abstract] [Full Text]  
• Liu, W., Ouyang, X., Yang, J., Liu, J., Li, Q., Gu, Y., Fukata, M., Lin, T., He, J. C., Abreu, M., Unkeless, J. C., Mayer, L., Xiong, H. (2009). AP-1 Activated by Toll-like Receptors Regulates Expression of IL-23 p19. J. Biol. Chem. 284: 24006-24016 [Abstract] [Full Text]  
• Mildner, A., Mack, M., Schmidt, H., Bruck, W., Djukic, M., Zabel, M. D., Hille, A., Priller, J., Prinz, M. (2009). CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system. Brain 132: 2487-2500 [Abstract] [Full Text]  
• Goodman, W. A., Levine, A. D., Massari, J. V., Sugiyama, H., McCormick, T. S., Cooper, K. D. (2009). IL-6 Signaling in Psoriasis Prevents Immune Suppression by Regulatory T Cells. J. Immunol. 183: 3170-3176 [Abstract] [Full Text]  
• Miossec, P., Korn, T., Kuchroo, V. K. (2009). Interleukin-17 and Type 17 Helper T Cells. NEJM 361: 888-898 [Full Text]  
• Kuwabara, T., Ishikawa, F., Yasuda, T., Aritomi, K., Nakano, H., Tanaka, Y., Okada, Y., Lipp, M., Kakiuchi, T. (2009). CCR 7 Ligands Are Required for Development of Experimental Autoimmune Encephalomyelitis through Generating IL-23-Dependent Th17 Cells. J. Immunol. 183: 2513-2521 [Abstract] [Full Text]  
• Elyaman, W., Bradshaw, E. M., Uyttenhove, C., Dardalhon, V., Awasthi, A., Imitola, J., Bettelli, E., Oukka, M., van Snick, J., Renauld, J.-C., Kuchroo, V. K., Khoury, S. J. (2009). IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc. Natl. Acad. Sci. USA 106: 12885-12890 [Abstract] [Full Text]  
• Xu, J., Wagoner, G., Douglas, J. C., Drew, P. D. (2009). Liver X receptor agonist regulation of Th17 lymphocyte function in autoimmunity. J. Leukoc. Biol. 86: 401-409 [Abstract] [Full Text]  
• Brereton, C. F., Sutton, C. E., Lalor, S. J., Lavelle, E. C., Mills, K. H. G. (2009). Inhibition of ERK MAPK Suppresses IL-23- and IL-1-Driven IL-17 Production and Attenuates Autoimmune Disease. J. Immunol. 183: 1715-1723 [Abstract] [Full Text]  
• Paidipally, P., Periasamy, S., Barnes, P. F., Dhiman, R., Indramohan, M., Griffith, D. E., Cosman, D., Vankayalapati, R. (2009). NKG2D-Dependent IL-17 Production by Human T Cells in Response to an Intracellular Pathogen. J. Immunol. 183: 1940-1945 [Abstract] [Full Text]  
• Walsh, K. P., Brady, M. T., Finlay, C. M., Boon, L., Mills, K. H. G. (2009). Infection with a Helminth Parasite Attenuates Autoimmunity through TGF-{beta}-Mediated Suppression of Th17 and Th1 Responses. J. Immunol. 183: 1577-1586 [Abstract] [Full Text]  
• Hollis-Moffatt, J E, Merriman, M E, Rodger, R A, Rowley, K A, Chapman, P T, Dalbeth, N, Gow, P J, Harrison, A A, Highton, J, Jones, P B B, O'Donnell, J L, Stamp, L K, Merriman, T R (2009). Evidence for association of an interleukin 23 receptor variant independent of the R381Q variant with rheumatoid arthritis. Ann Rheum Dis 68: 1340-1344 [Abstract] [Full Text]  
• Fang, C., Zhang, X., Miwa, T., Song, W.-C. (2009). Complement promotes the development of inflammatory T-helper 17 cells through synergistic interaction with Toll-like receptor signaling and interleukin-6 production. Blood 114: 1005-1015 [Abstract] [Full Text]  
• Vojdani, A., Lambert, J. (2009). The Role of Th17 in Neuroimmune Disorders: Target for CAM Therapy. Part I. Evid Based Complement Alternat Med 0: nep062v1-nep062 [Abstract] [Full Text]  
• von Vietinghoff, S., Ley, K. (2009). IL-17A Controls IL-17F Production and Maintains Blood Neutrophil Counts in Mice. J. Immunol. 183: 865-873 [Abstract] [Full Text]  
• Zhang, X., Gao, L., Lei, L., Zhong, Y., Dube, P., Berton, M. T., Arulanandam, B., Zhang, J., Zhong, G. (2009). A MyD88-Dependent Early IL-17 Production Protects Mice against Airway Infection with the Obligate Intracellular Pathogen Chlamydia muridarum. J. Immunol. 183: 1291-1300 [Abstract] [Full Text]  
• He, D., Wu, L., Kim, H. K., Li, H., Elmets, C. A., Xu, H. (2009). IL-17 and IFN-{gamma} Mediate the Elicitation of Contact Hypersensitivity Responses by Different Mechanisms and Both Are Required for Optimal Responses. J. Immunol. 183: 1463-1470 [Abstract] [Full Text]  
• Yang, Y., Weiner, J., Liu, Y., Smith, A. J., Huss, D. J., Winger, R., Peng, H., Cravens, P. D., Racke, M. K., Lovett-Racke, A. E. (2009). T-bet is essential for encephalitogenicity of both Th1 and Th17 cells. JEM 206: 1549-1564 [Abstract] [Full Text]  
• Uemura, Y., Liu, T.-Y., Narita, Y., Suzuki, M., Nakatsuka, R., Araki, T., Matsumoto, M., Iwai, L. K., Hirosawa, N., Matsuoka, Y., Murakami, M., Kimura, T., Hase, M., Kohno, H., Sasaki, Y., Ichihara, Y., Ishihara, O., Kikuchi, H., Sakamoto, Y., Jiao, S.-C., Senju, S., Sonoda, Y. (2009). Cytokine-Dependent Modification of IL-12p70 and IL-23 Balance in Dendritic Cells by Ligand Activation of V{alpha}24 Invariant NKT Cells. J. Immunol. 183: 201-208 [Abstract] [Full Text]  
• Chen, C., Liu, X., Wan, B., Zhang, J. Z. (2009). Regulatory Properties of Copolymer I in Th17 Differentiation by Altering STAT3 Phosphorylation. J. Immunol. 183: 246-253 [Abstract] [Full Text]  
• Cui, Y., Shao, H., Lan, C., Nian, H., O'Brien, R. L., Born, W. K., Kaplan, H. J., Sun, D. (2009). Major Role of {gamma}{delta} T Cells in the Generation of IL-17+ Uveitogenic T Cells. J. Immunol. 183: 560-567 [Abstract] [Full Text]  
• Staschke, K. A., Dong, S., Saha, J., Zhao, J., Brooks, N. A., Hepburn, D. L., Xia, J., Gulen, M. F., Kang, Z., Altuntas, C. Z., Tuohy, V. K., Gilmour, R., Li, X., Na, S. (2009). IRAK4 Kinase Activity Is Required for Th17 Differentiation and Th17-Mediated Disease. J. Immunol. 183: 568-577 [Abstract] [Full Text]  
• Jin, W., Zhou, X.-F., Yu, J., Cheng, X., Sun, S.-C. (2009). Regulation of Th17 cell differentiation and EAE induction by MAP3K NIK. Blood 113: 6603-6610 [Abstract] [Full Text]  
• Sa-Nunes, A., Bafica, A., Antonelli, L. R., Choi, E. Y., Francischetti, I. M. B., Andersen, J. F., Shi, G.-P., Chavakis, T., Ribeiro, J. M., Kotsyfakis, M. (2009). The Immunomodulatory Action of Sialostatin L on Dendritic Cells Reveals Its Potential to Interfere with Autoimmunity. J. Immunol. 182: 7422-7429 [Abstract] [Full Text]  
• Li, B., Reynolds, J. M., Stout, R. D., Bernlohr, D. A., Suttles, J. (2009). Regulation of Th17 Differentiation by Epidermal Fatty Acid-Binding Protein. J. Immunol. 182: 7625-7633 [Abstract] [Full Text]  
• Spach, K. M., Noubade, R., McElvany, B., Hickey, W. F., Blankenhorn, E. P., Teuscher, C. (2009). A Single Nucleotide Polymorphism in Tyk2 Controls Susceptibility to Experimental Allergic Encephalomyelitis. J. Immunol. 182: 7776-7783 [Abstract] [Full Text]  
• Nath, N., Khan, M., Paintlia, M. K., Hoda, M. N., Giri, S. (2009). Metformin Attenuated the Autoimmune Disease of the Central Nervous System in Animal Models of Multiple Sclerosis. J. Immunol. 182: 8005-8014 [Abstract] [Full Text]  
• Blander, J. M., Amsen, D. (2009). Amino Acid Addiction. Science 324: 1282-1283 [Abstract] [Full Text]  
• Sundrud, M. S., Koralov, S. B., Feuerer, M., Calado, D. P., Kozhaya, A. E., Rhule-Smith, A., Lefebvre, R. E., Unutmaz, D., Mazitschek, R., Waldner, H., Whitman, M., Keller, T., Rao, A. (2009). Halofuginone Inhibits TH17 Cell Differentiation by Activating the Amino Acid Starvation Response. Science 324: 1334-1338 [Abstract] [Full Text]  
• Nady, S., Ignatz-Hoover, J., Shata, M. T. (2009). Interleukin-12 Is the Optimum Cytokine To Expand Human Th17 Cells In Vitro. CVI 16: 798-805 [Abstract] [Full Text]  
• Klemann, C., Raveney, B. J.E., Klemann, A. K., Ozawa, T., von Horsten, S., Shudo, K., Oki, S., Yamamura, T. (2009). Synthetic Retinoid AM80 Inhibits Th17 Cells and Ameliorates Experimental Autoimmune Encephalomyelitis. Am. J. Pathol. 174: 2234-2245 [Abstract] [Full Text]  
• Nistala, K., Wedderburn, L. R. (2009). Th17 and regulatory T cells: rebalancing pro- and anti-inflammatory forces in autoimmune arthritis. Rheumatology (Oxford) 48: 602-606 [Abstract] [Full Text]  
• Saeki, K., Fukuyama, S., Ayada, T., Nakaya, M., Aki, D., Takaesu, G., Hanada, T., Matsumura, Y., Kobayashi, T., Nakagawa, R., Yoshimura, A. (2009). A Major Lipid Raft Protein Raftlin Modulates T Cell Receptor Signaling and Enhances Th17-Mediated Autoimmune Responses. J. Immunol. 182: 5929-5937 [Abstract] [Full Text]  
• Awasthi, A., Kuchroo, V. K. (2009). Th17 cells: from precursors to players in inflammation and infection. Int Immunol 21: 489-498 [Abstract] [Full Text]  
• Siegemund, S., Schutze, N., Schulz, S., Wolk, K., Nasilowska, K., Straubinger, R. K., Sabat, R., Alber, G. (2009). Differential IL-23 requirement for IL-22 and IL-17A production during innate immunity against Salmonella enterica serovar Enteritidis. Int Immunol 21: 555-565 [Abstract] [Full Text]  
• Pastor, S., Minguela, A., Mi, W., Ward, E. S. (2009). Autoantigen Immunization at Different Sites Reveals a Role for Anti-Inflammatory Effects of IFN-{gamma} in Regulating Susceptibility to Experimental Autoimmune Encephalomyelitis. J. Immunol. 182: 5268-5275 [Abstract] [Full Text]  
• Diveu, C., McGeachy, M. J., Boniface, K., Stumhofer, J. S., Sathe, M., Joyce-Shaikh, B., Chen, Y., Tato, C. M., McClanahan, T. K., de Waal Malefyt, R., Hunter, C. A., Cua, D. J., Kastelein, R. A. (2009). IL-27 Blocks RORc Expression to Inhibit Lineage Commitment of Th17 Cells. J. Immunol. 182: 5748-5756 [Abstract] [Full Text]  
• Paust, H.-J., Turner, J.-E., Steinmetz, O. M., Peters, A., Heymann, F., Holscher, C., Wolf, G., Kurts, C., Mittrucker, H.-W., Stahl, R. A.K., Panzer, U. (2009). The IL-23/Th17 Axis Contributes to Renal Injury in Experimental Glomerulonephritis. J. Am. Soc. Nephrol. 20: 969-979 [Abstract] [Full Text]  
• Ooi, J. D., Phoon, R. K.S., Holdsworth, S. R., Kitching, A. R. (2009). IL-23, not IL-12, Directs Autoimmunity to the Goodpasture Antigen. J. Am. Soc. Nephrol. 20: 980-989 [Abstract] [Full Text]  
• Mangalam, A., Luckey, D., Basal, E., Jackson, M., Smart, M., Rodriguez, M., David, C. (2009). HLA-DQ8 (DQB1*0302)-Restricted Th17 Cells Exacerbate Experimental Autoimmune Encephalomyelitis in HLA-DR3-Transgenic Mice. J. Immunol. 182: 5131-5139 [Abstract] [Full Text]  
• Joshi, A. D., Fong, D. J., Oak, S. R., Trujillo, G., Flaherty, K. R., Martinez, F. J., Hogaboam, C. M. (2009). Interleukin-17-mediated Immunopathogenesis in Experimental Hypersensitivity Pneumonitis. Am. J. Respir. Crit. Care Med. 179: 705-716 [Abstract] [Full Text]  
• Lemos, H. P., Grespan, R., Vieira, S. M., Cunha, T. M., Verri, W. A. Jr., Fernandes, K. S. S., Souto, F. O., McInnes, I. B., Ferreira, S. H., Liew, F. Y., Cunha, F. Q. (2009). Prostaglandin mediates IL-23/IL-17-induced neutrophil migration in inflammation by inhibiting IL-12 and IFN{gamma} production. Proc. Natl. Acad. Sci. USA 106: 5954-5959 [Abstract] [Full Text]  
• Skarica, M., Wang, T., McCadden, E., Kardian, D., Calabresi, P. A., Small, D., Whartenby, K. A. (2009). Signal Transduction Inhibition of APCs Diminishes Th17 and Th1 Responses in Experimental Autoimmune Encephalomyelitis. J. Immunol. 182: 4192-4199 [Abstract] [Full Text]  
• Gocke, A. R., Hussain, R. Z., Yang, Y., Peng, H., Weiner, J., Ben, L.-H., Drew, P. D., Stuve, O., Lovett-Racke, A. E., Racke, M. K. (2009). Transcriptional Modulation of the Immune Response by Peroxisome Proliferator-Activated Receptor-{alpha} Agonists in Autoimmune Disease. J. Immunol. 182: 4479-4487 [Abstract] [Full Text]  
• Yoshimura, T., Sonoda, K.-H., Ohguro, N., Ohsugi, Y., Ishibashi, T., Cua, D. J., Kobayashi, T., Yoshida, H., Yoshimura, A. (2009). Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology (Oxford) 48: 347-354 [Abstract] [Full Text]  
• Eid, R. E., Rao, D. A., Zhou, J., Lo, S.-f. L., Ranjbaran, H., Gallo, A., Sokol, S. I., Pfau, S., Pober, J. S., Tellides, G. (2009). Interleukin-17 and Interferon-{gamma} Are Produced Concomitantly by Human Coronary Artery-Infiltrating T Cells and Act Synergistically on Vascular Smooth Muscle Cells. Circulation 119: 1424-1432 [Abstract] [Full Text]  
• Boniface, K., Bak-Jensen, K. S., Li, Y., Blumenschein, W. M., McGeachy, M. J., McClanahan, T. K., McKenzie, B. S., Kastelein, R. A., Cua, D. J., de Waal Malefyt, R. (2009). Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. JEM 206: 535-548 [Abstract] [Full Text]  
• Lombardi, V., Van Overtvelt, L., Horiot, S., Moingeon, P. (2009). Human Dendritic Cells Stimulated via TLR7 and/or TLR8 Induce the Sequential Production of Il-10, IFN-{gamma}, and IL-17A by Naive CD4+ T Cells. J. Immunol. 182: 3372-3379 [Abstract] [Full Text]  
• Hamada, H., Garcia-Hernandez, M. d. l. L., Reome, J. B., Misra, S. K., Strutt, T. M., McKinstry, K. K., Cooper, A. M., Swain, S. L., Dutton, R. W. (2009). Tc17, a Unique Subset of CD8 T Cells That Can Protect against Lethal Influenza Challenge. J. Immunol. 182: 3469-3481 [Abstract] [Full Text]  
• Gonzalez-Garcia, I., Zhao, Y., Ju, S., Gu, Q., Liu, L., Kolls, J. K., Lu, B. (2009). IL-17 Signaling-Independent Central Nervous System Autoimmunity Is Negatively Regulated by TGF-{beta}. J. Immunol. 182: 2665-2671 [Abstract] [Full Text]  
• Perona-Wright, G., Jenkins, S. J., O'Connor, R. A., Zienkiewicz, D., McSorley, H. J., Maizels, R. M., Anderton, S. M., MacDonald, A. S. (2009). A Pivotal Role for CD40-Mediated IL-6 Production by Dendritic Cells during IL-17 Induction In Vivo. J. Immunol. 182: 2808-2815 [Abstract] [Full Text]  
• Zrioual, S., Ecochard, R., Tournadre, A., Lenief, V., Cazalis, M.-A., Miossec, P. (2009). Genome-Wide Comparison between IL-17A- and IL-17F-Induced Effects in Human Rheumatoid Arthritis Synoviocytes. J. Immunol. 182: 3112-3120 [Abstract] [Full Text]  
• Chang, M., Lee, A. J., Fitzpatrick, L., Zhang, M., Sun, S.-C. (2009). NF-{kappa}B1 p105 Regulates T Cell Homeostasis and Prevents Chronic Inflammation. J. Immunol. 182: 3131-3138 [Abstract] [Full Text]  
• Ke, Y., Liu, K., Huang, G.-Q., Cui, Y., Kaplan, H. J., Shao, H., Sun, D. (2009). Anti-Inflammatory Role of IL-17 in Experimental Autoimmune Uveitis. J. Immunol. 182: 3183-3190 [Abstract] [Full Text]  
• Zhu, J., Davidson, T. S., Wei, G., Jankovic, D., Cui, K., Schones, D. E., Guo, L., Zhao, K., Shevach, E. M., Paul, W. E. (2009). Down-regulation of Gfi-1 expression by TGF-{beta} is important for differentiation of Th17 and CD103+ inducible regulatory T cells. JEM 206: 329-341 [Abstract] [Full Text]  
• Pirofski, L.-a., Casadevall, A. (2009). Rethinking T cell immunity in oropharyngeal candidiasis. JEM 206: 269-273 [Abstract] [Full Text]  
• Jacob, N., Yang, H., Pricop, L., Liu, Y., Gao, X., Zheng, S. G., Wang, J., Gao, H.-X., Putterman, C., Koss, M. N., Stohl, W., Jacob, C. O. (2009). Accelerated Pathological and Clinical Nephritis in Systemic Lupus Erythematosus-Prone New Zealand Mixed 2328 Mice Doubly Deficient in TNF Receptor 1 and TNF Receptor 2 via a Th17-Associated Pathway. J. Immunol. 182: 2532-2541 [Abstract] [Full Text]  
• Zhu, Y., Hu, C., Lu, M., Liao, S., Marini, J. C., Yohrling, J., Yeilding, N., Davis, H. M., Zhou, H. (2009). Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL-12/23p40, in Patients With Moderate to Severe Plaque Psoriasis. J Clin Pharmacol 49: 162-175 [Abstract] [Full Text]  
• Hartupee, J., Liu, C., Novotny, M., Sun, D., Li, X., Hamilton, T. A. (2009). IL-17 Signaling for mRNA Stabilization Does Not Require TNF Receptor-Associated Factor 6. J. Immunol. 182: 1660-1666 [Abstract] [Full Text]  
• Rueda, B, Broen, J, Torres, O, Simeon, C, Ortego-Centeno, N, Schrijvenaars, M M V A P, Vonk, M C, Fonollosa, V, van den Hoogen, F H J, Coenen, M J H, Sanchez-Roman, J, Aguirre-Zamorano, M A, Garcia-Portales, R, Pros, A, Camps, M T, Gonzalez-Gay, M A, Martin, J, Radstake, T R D J (2009). The interleukin 23 receptor gene does not confer risk to systemic sclerosis and is not associated with systemic sclerosis disease phenotype. Ann Rheum Dis 68: 253-256 [Abstract] [Full Text]  
• Yang, K, Wen, J, Liu, X, Kijlstra, A, Chen, L, Chi, W, Zhou, H, Huang, X, Yang, P (2009). Inhibitory effect of rapamycin and dexamethasone on production of IL-17 and IFN-{gamma} in Vogt-Koyanagi-Harada patients. Br J Ophthalmol 93: 249-253 [Abstract] [Full Text]  
• Iezzi, G., Sonderegger, I., Ampenberger, F., Schmitz, N., Marsland, B. J., Kopf, M. (2009). CD40-CD40L cross-talk integrates strong antigenic signals and microbial stimuli to induce development of IL-17-producing CD4+ T cells. Proc. Natl. Acad. Sci. USA 106: 876-881 [Abstract] [Full Text]  
• Takatori, H., Kanno, Y., Watford, W. T., Tato, C. M., Weiss, G., Ivanov, I. I., Littman, D. R., O'Shea, J. J. (2009). Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. JEM 206: 35-41 [Abstract] [Full Text]  
• Mathers, A. R., Janelsins, B. M., Rubin, J. P., Tkacheva, O. A., Shufesky, W. J., Watkins, S. C., Morelli, A. E., Larregina, A. T. (2009). Differential Capability of Human Cutaneous Dendritic Cell Subsets to Initiate Th17 Responses. J. Immunol. 182: 921-933 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF, 260K) PPT slides of all figures Supplemental Material Index Alert me when this article is cited Citation Map Services Email this article Similar articles in this journal Similar articles in PubMed Alert me to new content in the JEM Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Langrish, C. L. Articles by Cua, D. J. Search for Related Content PubMed PubMed Citation Articles by Langrish, C. L. Articles by Cua, D. J. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Substance via MeSH Related Collections Related Article Social Bookmarking                            What's this?